Evidence map›Paper›PMID 34012389›Full record

ArticleFrontiers in pharmacology2021

Centhaquine Restores Renal Blood Flow and Protects Tissue Damage After Hemorrhagic Shock and Renal Ischemia.

Amaresh K Ranjan, Zhong Zhang, Seema Briyal, Anil Gulati

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05241067 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Multicentric, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Centhaquine as an Adjuvant to the Standard of Care in Patients With Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

TypeinterventionalSponsorPharmazz, Inc.Ran2026 to 2026Enrolled80ConditionsAcute Respiratory Distress Syndrome (ARDS)ArmsNormal Saline, Centhaquine
NCT05251181 phase3not yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Multi-Centric, Randomized, Double-Blind, Placebo-controlled, Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent to be Used as an Adjuvant to Standard Treatment of Hypovolemic Shock

TypeinterventionalSponsorPharmazz, Inc.Ran2026 to 2027Enrolled430ConditionsHypovolemic ShockArmsNormal Saline, Centhaquine
NCT05956418 phase4recruitingnot on this map

A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of Shock

TypeinterventionalSponsorPharmazz, Inc.Ran2021 to 2026Enrolled400ConditionsHypovolemic ShockArmsCenthaquine
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Role of adrenergic receptors in shock.Frontiers in physiology · 2023
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Amaresh K RanjanChicago College of Pharmacy, Midwestern University, Downers Grove, IL, United States.
Zhong ZhangChicago College of Pharmacy, Midwestern University, Downers Grove, IL, United States.
Seema BriyalChicago College of Pharmacy, Midwestern University, Downers Grove, IL, United States.
Anil GulatiChicago College of Pharmacy, Midwestern University, Downers Grove, IL, United States.
Midwestern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

acute kidney injurycenthaquinehemorrhagehypoxia inducible factorsresuscitationshock

Identifiers

PMID34012389
PMCPMC8126696
OpenAlexW3158760648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.